Author: admin

Vipergen EPO Patent Maintained Following Opposition

Written by admin on May 20, 2026. Posted in News. No Comments on Vipergen EPO Patent Maintained Following Opposition

Vipergen ApS is pleased to announce that European patent EP3914704B1, covering Vipergen’s proprietary cellular Binder Trap Enrichment (cBTE) technology, has been maintained as granted following the EPO Opposition Oral Proceedings held on May 19, 2026. The European Patent Office (EPO) rejected the opposition filed by Amgen/Nuevolution A/S.

The cBTE technology enables small molecule DEL screening to be performed directly inside a living cell, eliminating the need for purified protein and providing physiologically relevant conditions. This opens new possibilities for targeting previously intractable proteins such as transcription factors and intrinsically disordered proteins.

“This is an important outcome for Vipergen and a strong validation of the novelty and inventiveness of our cBTE technology,” said CEO Nils Hansen, PhD at Vipergen. “We are confident in the strength of our intellectual property portfolio and remain fully committed to advancing cell-based DEL screening as a platform for next-generation drug discovery.”

The maintained patent strengthens Vipergen’s intellectual property position and underlines its status as the first and only company capable of screening DELs inside a living cell.

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit https://www.vipergen.com.

For additional information please contact:

Vipergen ApS
info@vipergen.com

New High-Throughput Workflow Streamlines Building Block Conjugation for DNA-Encoded Library Synthesis

Written by admin on May 20, 2026. Posted in News. No Comments on New High-Throughput Workflow Streamlines Building Block Conjugation for DNA-Encoded Library Synthesis

Researchers at Vipergen have developed a fast and cost-effective 96-well plate workflow for the conjugation of building blocks to DNA, streamlining the preparation of key components for DNA-encoded library (DEL) synthesis.

A critical step in DEL preparation is the conjugation of building blocks to DNA – a process that becomes increasingly time-consuming and technically demanding when scaled to the hundreds or thousands of building blocks. The new workflow, published in Bioconjugate Chemistry, addresses this directly by integrating codon ligation, ester hydrolysis, and building block conjugation into a single pot process carried out entirely in 96-well plates. By minimizing liquid transfers and handling steps, the method significantly reduces hands-on time without compromising product quality.

A central feature of the study is the systematic evaluation of two amine protecting group strategies: Boc and pNs – across 278 building blocks spanning 15 scaffold classes. While Boc protection performed well for most compounds, the authors identified several cases where switching to the milder pNs deprotection conditions proved decisive in recovering good yields, demonstrating the complementarity of the two strategies.

“We wanted a process that could handle hundreds of building blocks without becoming a bottleneck. By keeping everything in 96-well plates from start to finish, we significantly cut down hands-on time while maintaining the quality needed for DEL synthesis,” said Senior Scientist Dr. Peter Blakskjær, lead author of the study.

The practical value of the workflow was validated by incorporating all conjugates into DELs using Vipergen’s yoctoreactor platform, with DNA codon integrity confirmed by sequencing and building block identity and purity verified by HPLC-MS. Compatible with both templated and split-and-mix DEL formats, the authors also note broader relevance for the wider bioconjugation community.

Find the paper here: https://doi.org/10.1021/acs.bioconjchem.6c00010

About Vipergen:

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Vipergen Expands Glue Screening with Five E3 Ubiquitin Ligases

Written by admin on May 12, 2026. Posted in News. No Comments on Vipergen Expands Glue Screening with Five E3 Ubiquitin Ligases

Vipergen has expanded its cell-based molecular glue screening platform with five E3 ubiquitin ligases: FBXO22, FEM1B, KBTBD4, SKP2 and SPOP – bringing the total number of ready-to-use ligases for screening to 25.

With more than 600 identified in humans, E3 ubiquitin ligases play a central role in protein turnover and are essential to targeted protein degradation. By expanding its ligase panel, Vipergen enables partners to explore broader biological space and improve the chances of identifying molecular glue or PROTAC degraders for their targets. In addition, Vipergen offers tailored solutions, enabling rapid incorporation of new E3 ligases into its screening platform.

The newly incorporated ligases were selected based on features relevant to the drug discovery community, including robust expression in disease-relevant tissues, ligandability, compatibility with degrader modalities, interaction with disease-relevant targets and overall diversity to expand target space.

“With the addition of these five ligases, we continue to push the boundaries of what is possible in molecular glue discovery,” said Dr. Allan B. Christensen, Director of Screening Technologies at Vipergen. “Expanding our ligase panel enhances our ability to identify unique protein-protein interaction inducers and deliver high-quality starting points for drug discovery programs.”

This expansion further strengthens Vipergen’s position at the forefront of molecular glue discovery and reflects its mission to accelerate the discovery of next-generation therapeutics through novel modalities.

About Vipergen ApS

For additional information please contact:

Vipergen ApS
info@vipergen.com

Vipergen Publishes Review on the Expanding Role of Chemical Libraries in Next-Generation Drug Discovery

Written by admin on April 29, 2026. Posted in News. No Comments on Vipergen Publishes Review on the Expanding Role of Chemical Libraries in Next-Generation Drug Discovery

Vipergen senior scientist Tobias N. Hansen and CEO Nils J. V. Hansen have authored a review, Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for their Synthesis, highlighting how modern chemical libraries are helping researchers exploring chemical space more effectively in the search for new drug candidates. The paper now published in ChemistryEurope, outlines practical ways to design, compare, and select libraries for different discovery challenges, with a focus on how molecular diversity can be measured and built into screening collections.

The review covers both traditional small-molecule screening collections and newer affinity-selection formats, including DNA-encoded libraries (DELs), peptide-encoded libraries, and self-encoded libraries. It also examines synthetic strategies such as diversity-oriented synthesis, biology-oriented synthesis, and late-stage skeletal edition, showing how advances in chemistry continue to expand the scope of compounds available for drug discovery.

A key message of the paper is that library quality matters as much as, or more than, library size. Looking ahead, the authors points to improved library purity, broader encoded chemistry, stronger computational workflows, and incorporation of AI as important drivers for the next generation of drug discovery.

The review is published in ChemistryEurope, the new flagship journal of the Chemistry Europe publishing association. The journal is open to all, hereby serving the global community with an open-access platform for exciting discoveries.

Find the paper here

About Vipergen:

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Vipergen launches new DEL series with Lib100 and updates Series 50 to Lib058

Written by admin on October 7, 2025. Posted in News. No Comments on Vipergen launches new DEL series with Lib100 and updates Series 50 to Lib058

Vipergen has synthesized and released Lib100, the first library in a new DNA-encoded library (DEL) series, while also upgrading the Series 50 collection from Lib057 to Lib058.

About Lib100

Built using well-established DEL chemistry (amide formation and reductive amination) and powered by Vipergen’s Yoctoreactor® technology, Lib100 delivers a high-fidelity library with a one-to-one match between DNA barcode and encoded small molecule. The majority of building blocks are synthesized in-house, broadening chemical diversity and enabling exploration of under-represented chemical space.

Lib100 was developed to produce molecules slightly larger than the Series 50 libraries, which we believe is suitable for targets with larger and more shallow binding pockets along with the discovery of protein-protein interaction inhibitors.

Scale: Lib100 comprises 511 million compounds.

Designed-in drug-likeness

Lib100 was engineered to balance ADME-relevant properties from the outset:

Lipophilicity: Avg. cLogP 1.6
Hydrogen bonding: Avg. 6.9 H-bond acceptors (HBA) and 2.5 H-bond donors (HBD)
Rule of 5: >99% of compounds comply with Lipinski’s Ro5 and Avg. MW of 598 Da
Three-dimensionality: Avg. Fsp3 = 0.51; >96% of compounds have Fsp3 ≥ 0.3
Aromaticity: Avg. 2.9 aromatic rings; >98% of compounds have ≤ 4 aromatic rings

These parameters support the probability for high aqueous solubility and cell permeability while keeping compounds squarely in drug-like space

Series 50 update: Lib058

In parallel, Vipergen has refreshed the Series 50 library to Lob058, introducing additional designer building blocks and removing legacy components that did not meet current standards. Like Lib100, Lib058 is Ro5-compliant and designed to generate hits with a high probability to be drug-like and cell-permeable.

Scale: Lib058 comprises 603 million compounds.

Interested in collaborating? Contact us to discuss screens, custom selections, and partnership opportunities.

React more about Vipergen’s DEL screening technologies here.

Overview of Vipergens Libraries

Parameter	Lib047	Lib058	Lib081	Lib100
Size (million of compounds)	499	603	381	511
Chemistries	Acylation Red. amination SNAr	Acylation Red. amination	Acylation Red. amination	Acylation Red. amination
Compounds w 1 cyclic, tertiary amide	48%	50%	52%	37%
Compounds w 2 cyclic, tertiary amides	–	34%	33%	57%
Total number of building blocks (#)	1580	1339	1138	1043
Designer building blocks (#)	948	657	617	635
Scaffolds (#)	394	353	295	323
Toxicophores (%)	1.0	1.3	1.1	2.2
Molecular weight (avg)	605	503	525	598
cLogP (avg)	2.7	2.8	2.9	2.6
HBA (avg)	8.6	6.0	6.2	6.9
HBD (avg)	2.8	2.8	2.9	2.5
Rotatable bonds (avg)	10.5	8.3	8.9	9.2
TPSA (avg)	152	135	137	144
Fsp³ (avg)	0.5	0.6	0.6	0.5
Suitability for difficult targets	***	**	**	***

SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services

Written by admin on November 11, 2024. Posted in News. No Comments on SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services

SARomics Biostructures AB and Vipergen ApS announced today a strategic partnership with the goal to offer enhanced hit and lead identification services based on their complementary technology platforms. By combining Vipergen’s DEL screening technologies with SARomics structural biology capabilities, the companies will enhance their drug discovery services by offering expedited hit identification and lead generation.

Vipergen’s high-fidelity DNA encoded library (DEL) screening technologies enable the identification of novel hit compounds by screening 500+ million drug-like molecules in a single tube or in living cells. Structural information involving detailed information about binding sites and binding poses of identified compounds can rapidly be generated by utilizing SARomics Biostructures structural biology capabilities. This combined information will greatly enhance and accelerate subsequent lead generation of identified hit compounds.

“The collaboration with Vipergen will leverage hit identification and lead generation towards challenging targets and accelerate the discovery of novel therapies” commented Björn Walse, Chief Executive Officer of SARomics.

“Vipergen is pleased to enter into a strategic collaboration with SARomics, a recognized leader in the structural biology field whose high-quality proteins meet all requirements for successful DEL screens,” said Nils Hansen, Chief Executive Officer of Vipergen. “We are excited to leverage our collaboration with SARomics to facilitate even better outcomes for Vipergen’s drug discovery clients.”

About SARomics Biostructures AB

SARomics Biostructures, Lund, Sweden provides structural biology and structure-based drug design services to biotech, pharmaceutical, and academic organizations. SARomics has built a global reputation for its structural biology skills and is currently supporting clients in North America, Europe and Japan to pursue their drug discovery objectives. For more information, please visit www.saromics.com.

About Vipergen ApS

For additional information please contact:

Dr. Björn Walse, CEO
SARomics Biostructures AB
sales@saromics.com

Dr. Nils Jakob Vest Hansen, CEO
Vipergen ApS
info@vipergen.com

Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.

Written by admin on April 19, 2024. Posted in News. No Comments on Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.

The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein.
By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, the companies will integrate and enhance their end-to-end discovery solution, by offering expedited hit identification.
The two companies will also collaborate on advancing DEL technologies.

Hyderabad, India, and Copenhagen, Denmark; April 19, 2024: Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership. The collaboration aims to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service. The two companies will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering.

Vipergen’s high-fidelity DEL screening technologies would be a strategic addition to Aurigene’s existing small molecule discovery capabilities, from compound resynthesis to candidate nomination. With the addition of hit screening capabilities, Aurigene would be able to enhance its Integrated Drug Discovery (IDD) service offering to its global customers.

“The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer-centric approach. The recent launch of Aurigene.AI for small molecules and DEL partnership with Vipergen aim to reduce the hit finding timelines. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us.”, said Akhil Ravi, CEO, Aurigene.

“We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.”, said Nils Jakob Vest Hansen, PhD, CEO, Vipergen.

About Aurigene

Aurigene, a Dr. Reddy’s Laboratories company, is a global contract research, development, and manufacturing organization (CRDMO built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of small and large molecules. We offer integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing.

For more details about Aurigene, please visit www.aurigeneservices.com.

LinkedIn YouTube

About Vipergen

For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contacts:

Aurigene

ContactAPSL@aurigeneservices.com

Vipergen

info@vipergen.com

Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications

Written by admin on June 15, 2022. Posted in News. No Comments on Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications.

Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma targets. LEO Pharma will select hits for potential development into innovative drugs for dermatology applications. LEO Pharma will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“Driving our mission to rapidly bring better treatments to people with skin conditions, we continue to explore ways to discover novel small-molecule compounds for innovative and challenging targets while shortening development timelines,” said Thorsten Thormann, Vice President of Research & Early Development at LEO Pharma. “Partnering with Vipergen gives us access to the only technology capable of screening DEL libraries inside living cells, under physiologically relevant conditions. We look forward to a productive partnership.”

“We are very pleased to partner with LEO Pharma in its mission to develop first-in-class and best-in-class treatments for the millions of patients around the world suffering with psoriasis, eczema, acne, skin infections, and other serious skin conditions,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We look forward to applying our full suite of DEL screening technologies to accelerate and advance LEO Pharma’s efforts to discover novel, high-quality small molecules for development into innovative new treatments.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:

Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies

Written by admin on April 4, 2022. Posted in News. No Comments on Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target. Theseus will select hits for potential development into targeted tyrosine kinase inhibitors (TKIs) and will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“Screening small-molecule libraries inside living cells — in a physiologically relevant context — is particularly important for success in developing cancer therapeutics,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We are excited to apply our in-living-cell DEL screening technology to Theseus’ efforts to develop next-generation kinase inhibitors to transform the way cancer is treated.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes Research Partnership with Bayer to Discover Novel Compounds for Pharmaceuticals and More Sustainable Crop Protection Solutions

Written by admin on December 21, 2021. Posted in News. No Comments on Vipergen Establishes Research Partnership with Bayer to Discover Novel Compounds for Pharmaceuticals and More Sustainable Crop Protection Solutions

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions. Under the terms of the agreement, Vipergen will apply its new in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to selected Bayer protein targets. Bayer will select potential drug and crop protection development candidates based on the hits generated by Vipergen’s technology. Bayer will retain exclusive rights to globally commercialize all products resulting from the collaboration. Financial details of the partnership were not disclosed.

Vipergen’s Cellular Binder Trap Enrichment® (cBTE) technology is the first and only platform for screening DNA-encoded small-molecule libraries inside living cells. The technology is designed to accelerate and improve the success rate for discovering novel, high-quality small molecules against protein targets of interest, including challenging targets that are difficult to express and purify in an active form.

“We are looking forward to the partnership with Vipergen and to building on its new technology for screening DNA-encoded libraries under physiologically relevant conditions of living cells for the development of new products in health and agriculture,” said Monika Lessl, SVP and Head of Corporate R&D and Social Innovation at Bayer.

“We are very pleased to partner with Bayer, a life sciences leader in human health and agriculture,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We look forward to applying our Cellular Binder Trap Enrichment® technology to screen DNA-encoded libraries in living cells to support the development of new drugs and sustainable crop-protection solutions.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com